Company · compass-pathways-099cd74a
COMPASS Pathways
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. COMPASS Pathways. Companies, record compass-pathways-099cd74a. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/compass-pathways-099cd74a
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- COMPASS Pathways
- Trials
- 16
- As lead sponsor
- 9
- As collaborator
- 7
- Recruiting
- 2
- Active, recruiting or not
- 4
- Completed
- 9
- Stopped early, withdrawn or suspended
- 1
- Posted results
- 4
- Trials by phase
- Phase 2 12, Phase 3 4
- Drugs its trials test
- 1
- Comparisons calculated in its trials
- 0
- First trial registered
- 2018-12-13
- Last update
- 2026-11-12
Source ClinicalTrials.gov
Pipeline1
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets |
|---|---|---|---|---|---|---|---|
| PSILOCYBIN | Phase 3 | 15 | 8 | 2 | HTR2A | Serotonin 2a (5-HT2a) receptor agonist | https://conductscience.org/library/drugs/CHEMBL194378 |
Source Open Targets
Trials16
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07570654 | Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Lead sponsor | Phase 2/3 | Recruiting | Interventional | 300 | 2026-09-14 | PSILOCYBIN | https://conductscience.org/library/trials/NCT07570654 | ClinicalTrials.gov | |
| NCT06247839 | The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder | Collaborator | Phase 3 | Recruiting | Interventional | 20 | 2024-09-10 | PSILOCYBIN | https://conductscience.org/library/trials/NCT06247839 | ClinicalTrials.gov | |
| NCT05733546 | A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder | Lead sponsor | Phase 2 | Active, not recruiting | Interventional | 102 | 2023-01-30 | PSILOCYBIN | https://conductscience.org/library/trials/NCT05733546 | ClinicalTrials.gov | |
| NCT05711940 | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | Lead sponsor | Phase 3 | Active, not recruiting | Interventional | 572 | 2023-02-14 | PSILOCYBIN | https://conductscience.org/library/trials/NCT05711940 | ClinicalTrials.gov | |
| NCT05624268 | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | Lead sponsor | Phase 3 | Completed | Interventional | 258 | 2023-01-24 | PSILOCYBIN | https://conductscience.org/library/trials/NCT05624268 | ClinicalTrials.gov | |
| NCT05481736 | Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study | Lead sponsor | Phase 2 | Completed | Interventional | 32 | 2022-10-12 | PSILOCYBIN | https://conductscience.org/library/trials/NCT05481736 | ClinicalTrials.gov | |
| NCT05381974 | The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD | Collaborator | Phase 2 | Withdrawn | Interventional | 0 | 2022-09-15 | PSILOCYBIN | https://conductscience.org/library/trials/NCT05381974 | ClinicalTrials.gov | |
| NCT05312151 | The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Lead sponsor | Phase 2 | Completed | Interventional | 22 | 2022-06-10 | 2025-06-13 | PSILOCYBIN | https://conductscience.org/library/trials/NCT05312151 | ClinicalTrials.gov |
| NCT05220410 | The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation | Collaborator | Phase 2 | Completed | Interventional | 20 | 2022-03-28 | PSILOCYBIN | https://conductscience.org/library/trials/NCT05220410 | ClinicalTrials.gov | |
| NCT04739865 | The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression | Lead sponsor | Phase 2 | Completed | Interventional | 19 | 2020-08-10 | 2023-11-09 | PSILOCYBIN | https://conductscience.org/library/trials/NCT04739865 | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsConditions11
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Treatment Resistant Depression | 8 |
| Anorexia Nervosa | 2 |
| Major Depressive Disorder | 2 |
| Body Dysmorphic Disorders | 1 |
| PTSD | 1 |
| PTSD - Post Traumatic Stress Disorder | 1 |
| PTSD Symptoms | 1 |
| PTSD, Post Traumatic Stress Disorder | 1 |
| Post Traumatic Stress Disorder | 1 |
| Suicidal Ideation | 1 |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 conditionsPartners6
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
| Organization | Class | Trials shared | In Companies | Source |
|---|---|---|---|---|
| Sheppard Pratt Health System | Other | 3 | ClinicalTrials.gov | |
| Massachusetts General Hospital | Other | 1 | ClinicalTrials.gov | |
| New York State Psychiatric Institute | Other | 1 | ClinicalTrials.gov | |
| Sharmin Ghaznavi | Other | 1 | ClinicalTrials.gov | |
| University of California, Los Angeles | Other | 1 | ClinicalTrials.gov | |
| University of California, San Diego | Other | 1 | ClinicalTrials.gov |
Data dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/compass-pathways-099cd74a
GET https://conductscience.org/api/companies/v1/compass-pathways-099cd74a/pipeline